subasumstat,pembrolizumab
takeda,merck
['sclc', 'nsclc', 'colorectal', 'rectal', 'pembrolizumab', 'subasumstat']
tomorrow, hear from s dr. sanjay goel at 2022 on the latest data from a phase 1b study of subasumstat in combination with pembrolizumab in patients with nsclc or microsatellite-stable colorectal #cancer. #asco2022 
Rutgers Cancer Institute of New Jersey is the state’s only NCI-designated Comprehensive Cancer Center and a leader in patient care and cancer research.